Noninvasive cytology-based assay could provide screening at a reasonable cost.
Biomoda and New Mexico Institute of Mining and Technology are partnering to develop a diagnostic product for lung cancer. The collaborators will work together on clinical studies to develop a specialized image-recognition technology.
This is a part of the company’s commercialization of its assay for the early detection of lung cancer. Biomoda’s technology, a noninvasive cytology-based assay, is designed for cancer screening of large populations at a reasonable cost.
Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive, according to the company.
